Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2016 ASCO Annual Meeting /
Intraperitoneal chemotherapy slows ovarian cancer progression

3rd - 7th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.16
Views: 1726

Dr Helen Mackay - Sunnybrook Research Institute, Toronto, Canada

Dr Mackay speaks with ecancertv at ASCO 2016 about ovarian cancer, and the therapeutic potential of added intraperitoneal (IP) chemotherapy.

IP chemotherapy allows the delivery of higher doses of chemotherapy to the tumour, while sparing other parts of the body from side effects.

For women who were initially treated with chemotherapy prior to surgery (eg., neoadjuvant therapy), the initial results from a randomised phase II trial show that 23.3% of women who received IP and IV chemotherapy had disease progression at nine months, vs. 42.2% of those who received IV chemotherapy alone.

A recording of the initial press conference can be found here, or click here for more from ASCO 2016

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation